Study Suggests Flaws in Standard Cognitive Alzheimer's Test Could Undermine Drug, Biomarker Research | GenomeWeb

According to a team led by researchers at Plymouth University, there are significant flaws in the standard cognitive test used to diagnose and evaluate Alzheimer's disease patients, which could be hampering efforts to develop treatments and biomarkers for the disease.

The test, called the Alzheimer's Disease Assessment Scale – Cognitive Behavior section, or ADAS-Cog, is particularly limited in its capacity to measure early-stage Alzheimer's disease, the researchers said, which could cause difficulties tracking the progression of such patients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: ancient Ethiopian genome indicates greater Eurasian backflow into Africa, sequencing to diagnose cutaneous T cell lymphoma, and more.

The US House of Representatives science committee has passed a bill to require NSF to ensure it only funds projects that are in the national interest.

DuPont teams with genome editing firm Caribou Biosciences for agricultural applications of the technology.

A blogger reviews her experience learning about her gut microbiome by shipping a sample to uBiome.